Ph.D. Sir Marc Feldmann - 08 Dec 2021 Form 4 Insider Report for 180 Life Sciences Corp. (ATNF)

Role
Director
Signature
/s/ Sir Marc Feldmann, Ph.D.
Issuer symbol
ATNF
Transactions as of
08 Dec 2021
Net transactions value
+$225,367
Form type
4
Filing time
13 Dec 2021, 15:18:55 UTC
Previous filing
05 Oct 2021
Next filing
08 Sep 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNF Common Stock Award $21,867 +5,536 +0.2% $3.95* 2,759,930 08 Dec 2021 Direct F1, F2
transaction ATNF Common Stock Purchase $203,500 +50,000 +1.8% $4.07* 2,809,930 09 Dec 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNF Stock Option (Right to Buy) Award $0 +25,000 $0.000000 25,000 08 Dec 2021 Common Stock 25,000 $3.95 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Granted to the Reporting Person pursuant to the Issuer's 2020 Omnibus Incentive Plan in consideration for services to be rendered. Exempt from Section 16(b) of the Securities Exchange Act of 1934 under Rule 16b-3.
F2 Represents shares of common stock issued in consideration for a net of $21,870 of compensation owed to the Reporting Person after the deduction for taxes for services rendered to the Company as a member of the Board of Directors.
F3 This transaction was executed in multiple trades at prices ranging from $4.05 to $4.10. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.